Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax plus tamoxifen for relapsed/refractory diffuse large B-cell lymphoma
NL-OMON51061Recruiting
- Sponsor
- University Medical Center Groningen
- Start
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of venetoclax and tamoxifen in diffuse large B-cell lymphoma (DLBCL), sponsored by University Medical Center Groningen. Primary endpoint: Safety and toxicity. Started Oct 2021; status: recruiting.
02
Drugs
venetoclaxtamoxifen
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NL-OMON51061.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51061.